JP2024541770A5 - - Google Patents

Info

Publication number
JP2024541770A5
JP2024541770A5 JP2024531094A JP2024531094A JP2024541770A5 JP 2024541770 A5 JP2024541770 A5 JP 2024541770A5 JP 2024531094 A JP2024531094 A JP 2024531094A JP 2024531094 A JP2024531094 A JP 2024531094A JP 2024541770 A5 JP2024541770 A5 JP 2024541770A5
Authority
JP
Japan
Prior art keywords
compound
administered
approximately
fesoterodine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541770A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080429 external-priority patent/WO2023097276A1/en
Publication of JP2024541770A publication Critical patent/JP2024541770A/ja
Publication of JP2024541770A5 publication Critical patent/JP2024541770A5/ja
Pending legal-status Critical Current

Links

JP2024531094A 2021-11-24 2022-11-23 神経障害の治療方法 Pending JP2024541770A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163283140P 2021-11-24 2021-11-24
US63/283,140 2021-11-24
US202263416745P 2022-10-17 2022-10-17
US63/416,745 2022-10-17
PCT/US2022/080429 WO2023097276A1 (en) 2021-11-24 2022-11-23 Methods of treating neurological disorders

Publications (2)

Publication Number Publication Date
JP2024541770A JP2024541770A (ja) 2024-11-12
JP2024541770A5 true JP2024541770A5 (https=) 2025-07-16

Family

ID=86540399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531094A Pending JP2024541770A (ja) 2021-11-24 2022-11-23 神経障害の治療方法

Country Status (9)

Country Link
US (1) US20250032460A1 (https=)
EP (1) EP4436564A4 (https=)
JP (1) JP2024541770A (https=)
KR (1) KR20240110642A (https=)
AU (1) AU2022396530A1 (https=)
CA (1) CA3239067A1 (https=)
IL (1) IL313067A (https=)
MX (1) MX2024006371A (https=)
WO (1) WO2023097276A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3061821T (pt) * 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
JP2013516497A (ja) * 2010-01-11 2013-05-13 ミスリィディオン,インク. 認知増強のための化合物と組成物、製造方法、および治療方法
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination

Similar Documents

Publication Publication Date Title
JP2505944B2 (ja) (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
TWI250016B (en) Use of pramipexole for the treatment of addictive disorders
JP2022544711A5 (https=)
JP2024540183A5 (https=)
IL178745A (en) Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma
JP2017061561A (ja) ニタゾキサニドの制御放出医薬配合物
JPH06102622B2 (ja) 肥満の治療
CN104349773A (zh) 用于治疗代谢性病症的组合物和方法
JP2026035701A5 (https=)
JP2024507810A5 (https=)
JP2023500032A5 (https=)
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2021502392A5 (https=)
JP2024531188A5 (https=)
JPS59193821A (ja) 抗不安薬としてのフルオキセチンの使用法
JP2023548429A5 (https=)
JP2002544227A5 (https=)
JP2023528896A5 (https=)
JP2022177119A5 (https=)
JP2004091473A (ja) 色素沈着改善治療薬
JP2024541770A5 (https=)
JP2023531930A5 (https=)
JP2021530568A5 (https=)
EP1345610B1 (en) Quetiapine for treating of dyskinesia in non-psychotic patients
CA2368352A1 (en) Method for treating neurodegeneration